Phase III Study of Sorafenib in Locally Advanced or Metastatic Patients with Radioactive Iodine Refractory Thyroid Cancer (DECISION) trial
{"Image DocumentName": "Phase III Study of Sorafenib in Locally Advanced or Metastatic Patients with Radioactive Iodine Refractory Thyroid Cancer (DECISION) trial", "Image ImageDescription": "Comparing the effect of sorafenib vs placebo on PFS in treatment of na\u00efve patients with RAI refractory, progressive metastatic DTC. Crossover or Continue Sorafenib. 400 mg PO BID. Progression. Off Study. Doctor\u2019s Decision. Disease Progression. Eligibility Criteria: Locally advanced or metastatic DTC. Progression within 14 months. RAI refractory. No prior targeted therapy, chemotherapy or thalidomide. Placebo. Randomisation (1:1) (n=380) Sorafenib 400 mg PO BID. There is on-going DECISION trial which finished enrollment. DECISION is phase III study of sorafenib in locally advanced or metastatic patients with radioactive iodine refractory thyroid cancers. It is going to compare the effect of sorafenib vs placebo on PFS in the patients with RAI refractory progressive DTCs. It finished enrollment of 380 eligible patients and on-going. In case of progression in patients on placebo, they can be switched to sorafenib treatment according to physicians decision.  NCT", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}